RU2012119247A - Модуляторы альфа-адренергических рецепторов - Google Patents
Модуляторы альфа-адренергических рецепторов Download PDFInfo
- Publication number
- RU2012119247A RU2012119247A RU2012119247/04A RU2012119247A RU2012119247A RU 2012119247 A RU2012119247 A RU 2012119247A RU 2012119247/04 A RU2012119247/04 A RU 2012119247/04A RU 2012119247 A RU2012119247 A RU 2012119247A RU 2012119247 A RU2012119247 A RU 2012119247A
- Authority
- RU
- Russia
- Prior art keywords
- dihydro
- amine
- pyrrole
- methylphenyl
- chloro
- Prior art date
Links
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 title 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- -1 methoxy, methyl Chemical group 0.000 claims abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 8
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 7
- 239000000460 chlorine Substances 0.000 claims abstract 7
- NJGBFOIJIHJNJA-UHFFFAOYSA-N n-(2-bromo-3-methoxyphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound COC1=CC=CC(NC=2CCCN=2)=C1Br NJGBFOIJIHJNJA-UHFFFAOYSA-N 0.000 claims abstract 5
- SUBQXOKGPRXCSZ-UHFFFAOYSA-N n-(2-bromo-3-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=CC=CC(NC=2CCCN=2)=C1Br SUBQXOKGPRXCSZ-UHFFFAOYSA-N 0.000 claims abstract 5
- VHSFGRXPOLXFPG-UHFFFAOYSA-N n-(2-chloro-3-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=CC=CC(NC=2CCCN=2)=C1Cl VHSFGRXPOLXFPG-UHFFFAOYSA-N 0.000 claims abstract 5
- XONSSXBDDPCFOG-UHFFFAOYSA-N n-(2-methoxy-3-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound COC1=C(C)C=CC=C1NC1=NCCC1 XONSSXBDDPCFOG-UHFFFAOYSA-N 0.000 claims abstract 5
- PIMNHRNLQIIVLL-UHFFFAOYSA-N n-(3-bromo-2-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=C(Br)C=CC=C1NC1=NCCC1 PIMNHRNLQIIVLL-UHFFFAOYSA-N 0.000 claims abstract 5
- SXCJOTBYRZWOEY-UHFFFAOYSA-N n-(3-chloro-2-methoxyphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound COC1=C(Cl)C=CC=C1NC1=NCCC1 SXCJOTBYRZWOEY-UHFFFAOYSA-N 0.000 claims abstract 5
- AHAXOGFRSICUFL-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=C(Cl)C=CC=C1NC1=NCCC1 AHAXOGFRSICUFL-UHFFFAOYSA-N 0.000 claims abstract 5
- AIHUCIJYZBMZBR-UHFFFAOYSA-N n-(3-fluoro-2-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=C(F)C=CC=C1NC1=NCCC1 AIHUCIJYZBMZBR-UHFFFAOYSA-N 0.000 claims abstract 5
- KKNXREUBALZMBT-UHFFFAOYSA-N n-(3-methoxy-2-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound COC1=CC=CC(NC=2CCCN=2)=C1C KKNXREUBALZMBT-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 4
- HIHWSJQZMNBSKQ-UHFFFAOYSA-N n-(3-chloro-2-fluorophenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound FC1=C(Cl)C=CC=C1NC1=NCCC1 HIHWSJQZMNBSKQ-UHFFFAOYSA-N 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 206010015150 Erythema Diseases 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- BKODVAMVJSKLFQ-UHFFFAOYSA-N n-(2,3-dimethylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=CC=CC(NC=2CCCN=2)=C1C BKODVAMVJSKLFQ-UHFFFAOYSA-N 0.000 claims 2
- ZBALZMHKFBREEV-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCC1 ZBALZMHKFBREEV-UHFFFAOYSA-N 0.000 claims 2
- SMJJQXVEBDICDZ-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=CC=CC(C)=C1NC1=NCCC1 SMJJQXVEBDICDZ-UHFFFAOYSA-N 0.000 claims 2
- DADXHMUZIXRGOH-UHFFFAOYSA-N n-(2-chlorophenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound ClC1=CC=CC=C1NC1=NCCC1 DADXHMUZIXRGOH-UHFFFAOYSA-N 0.000 claims 2
- PYBHARBPGDFRBG-UHFFFAOYSA-N n-(2-methylphenyl)-3,4-dihydro-2h-pyrrol-5-amine Chemical compound CC1=CC=CC=C1NC1=NCCC1 PYBHARBPGDFRBG-UHFFFAOYSA-N 0.000 claims 2
- OTEBHYPFOPLAGF-UHFFFAOYSA-N n-[2-(trifluoromethyl)phenyl]-3,4-dihydro-2h-pyrrol-5-amine Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NCCC1 OTEBHYPFOPLAGF-UHFFFAOYSA-N 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 abstract 4
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 abstract 1
- 0 *c1c(*)c(NC2=NCCC2)ccc1 Chemical compound *c1c(*)c(NC2=NCCC2)ccc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25365409P | 2009-10-21 | 2009-10-21 | |
| US61/253,654 | 2009-10-21 | ||
| PCT/US2010/053327 WO2011050030A1 (en) | 2009-10-21 | 2010-10-20 | Alpha adrenergic receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012119247A true RU2012119247A (ru) | 2013-11-27 |
Family
ID=43531175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012119247/04A RU2012119247A (ru) | 2009-10-21 | 2010-10-20 | Модуляторы альфа-адренергических рецепторов |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120238615A1 (enExample) |
| EP (1) | EP2491017B1 (enExample) |
| JP (1) | JP2013508384A (enExample) |
| KR (1) | KR20120098720A (enExample) |
| CN (1) | CN102666484A (enExample) |
| AU (1) | AU2010310800A1 (enExample) |
| BR (1) | BR112012011347A2 (enExample) |
| CA (1) | CA2778423A1 (enExample) |
| IN (1) | IN2012DN03844A (enExample) |
| RU (1) | RU2012119247A (enExample) |
| WO (1) | WO2011050030A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2699545T (pt) | 2011-04-19 | 2016-08-30 | Univ Strasbourg | Novos derivados amino-pirrolínicos, sua utilização na prevenção e/ou tratamento do síndrome metabólico |
| FR2974364B1 (fr) * | 2011-04-19 | 2013-10-11 | Univ Strasbourg | Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique |
| AU2014212274A1 (en) | 2013-02-01 | 2015-08-13 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
| CA2899342C (en) | 2013-02-01 | 2021-09-21 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| EP3866790A4 (en) | 2018-10-15 | 2022-08-03 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES |
| EP3870170B1 (en) | 2018-10-26 | 2026-02-25 | Opus Genetics, Inc. | Treatment of presbyopia and mydriasis with phentolamine |
| IT201900021435A1 (it) | 2019-11-18 | 2021-05-18 | Airmec Srl | Impianto idroelettrico a vite idrodinamica |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
-
2010
- 2010-10-20 KR KR1020127012916A patent/KR20120098720A/ko not_active Withdrawn
- 2010-10-20 JP JP2012535326A patent/JP2013508384A/ja active Pending
- 2010-10-20 AU AU2010310800A patent/AU2010310800A1/en not_active Abandoned
- 2010-10-20 US US13/502,871 patent/US20120238615A1/en not_active Abandoned
- 2010-10-20 EP EP10769130.5A patent/EP2491017B1/en not_active Not-in-force
- 2010-10-20 IN IN3844DEN2012 patent/IN2012DN03844A/en unknown
- 2010-10-20 BR BR112012011347A patent/BR112012011347A2/pt not_active IP Right Cessation
- 2010-10-20 CA CA2778423A patent/CA2778423A1/en not_active Abandoned
- 2010-10-20 CN CN2010800524204A patent/CN102666484A/zh active Pending
- 2010-10-20 RU RU2012119247/04A patent/RU2012119247A/ru not_active Application Discontinuation
- 2010-10-20 WO PCT/US2010/053327 patent/WO2011050030A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2491017A1 (en) | 2012-08-29 |
| IN2012DN03844A (enExample) | 2015-08-28 |
| BR112012011347A2 (pt) | 2019-09-24 |
| JP2013508384A (ja) | 2013-03-07 |
| WO2011050030A1 (en) | 2011-04-28 |
| CN102666484A (zh) | 2012-09-12 |
| US20120238615A1 (en) | 2012-09-20 |
| KR20120098720A (ko) | 2012-09-05 |
| AU2010310800A1 (en) | 2012-05-17 |
| CA2778423A1 (en) | 2011-04-28 |
| EP2491017B1 (en) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012119247A (ru) | Модуляторы альфа-адренергических рецепторов | |
| JP2014502979A5 (enExample) | ||
| NZ599136A (en) | Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors | |
| RU2498988C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| RU2009103675A (ru) | Производные бензимидазола в лечении расстройств, ассоциированных с ванилоидным рецептором trpv1 | |
| JP2013508384A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2005536475A5 (enExample) | ||
| UA109535C2 (uk) | Гетероциклічні карбоксаміди, які модулюють андрогенові рецептори, фармацевтична композиція на їх основі та спосіб лікування захворювань | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| EA200870360A1 (ru) | Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине | |
| JP2008110984A5 (enExample) | ||
| TN2009000160A1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| CA2777746A1 (en) | Benzoimidazole compounds and uses thereof | |
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| MX2009006795A (es) | Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. | |
| EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| EA201000702A1 (ru) | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| RU2010133483A (ru) | Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150428 |